Cohort study of FOLFIRINOX as third-line chemotherapy for metastatic pancreatic cancer.
Not Applicable
Recruiting
- Conditions
- nresectable pancreatic cancer
- Registration Number
- JPRN-UMIN000014259
- Lead Sponsor
- Kobe City Medical Center General Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1) active synchronous or metachronous malignancy other than carcinoma in situ 2) pregnant or nursing 3) severe mental disorders 4) serious coexisting illness 5) other medical condition unacceptable for entry
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method overall survival
- Secondary Outcome Measures
Name Time Method